CERo Therapeutics Holdings, Inc.
CERO
$0.04
$0.008.70%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -78.92% | -- | |||
| Gross Profit | 78.92% | -- | |||
| SG&A Expenses | 92.14% | -26.18% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.81% | -10.47% | |||
| Operating Income | 6.81% | 10.47% | |||
| Income Before Tax | 6.50% | 10.35% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 6.50% | 10.35% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 6.50% | 10.35% | |||
| EBIT | 6.81% | 10.47% | |||
| EBITDA | 6.86% | 10.60% | |||
| EPS Basic | 64.45% | 85.26% | |||
| Normalized Basic EPS | 92.11% | 65.41% | |||
| EPS Diluted | 64.45% | 85.26% | |||
| Normalized Diluted EPS | 92.11% | 65.41% | |||
| Average Basic Shares Outstanding | 1,084.52% | 159.15% | |||
| Average Diluted Shares Outstanding | 1,084.52% | 159.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||